Padagis Starts Life Post-Perrigo With Eucrisa Challenge
Anacor Sues Former Perrigo Rx Unit After Crisaborole Paragraph IV Filing
Padagis, the former Perrigo Rx business that was acquired by Altaris in July, has seen litigation initiated by Eucrisa originator Anacor over its Paragraph IV ANDA filing for crisaborole 2% ointment.
You may also be interested in...
Perrigo has announced a deal to acquire consumer healthcare company HRA Pharma for €1.8bn. The move comes after the firm shed the majority of its prescription pharmaceuticals interests in recent years and completes its transformation into a fully self-care focused company.
Perrigo has completed the divestment of its Rx prescription generics business to Altaris Capital Partners for $1.55bn, completing its transition to become a self-care consumer healthcare-focused company. Altaris has rebranded the unit as Padagis.
Perrigo has finally found the right deal to secure the long-awaited divestment of its prescription business, reaching an agreement worth just over $1.5bn with private equity firm Altaris Capital Partners.